Chronic Lymphocytic Leukemia Clinical Trial

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory leukemia-cll/" >chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and high-risk features must have failed at least 2 lines of prior therapy and participants with CLL or SLL and standard risk features must have failed at least 3 lines of prior therapy
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure
Has recovery to Grade ≤ 1 or baseline of any non-hematologic toxicities due to previous therapy, except alopecia (any Grade acceptable) and peripheral neuropathy (Grade ≤ 2 acceptable)

Exclusion Criteria:

Any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, that places the subject at unacceptable risk if they were to participate in the study
Systemic fungal, bacterial, viral, or other infection that is not controlled
Active autoimmune disease requiring immunosuppressive therapy
Progressive deep vein thrombosis or pulmonary embolism requiring treatment, but not yet on a stable anticoagulation regimen

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

65

Study ID:

NCT05244070

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 26 Locations for this study

See Locations Near You

University of Alabama at Birmingham-Medicine
Birmingham Alabama, 35249, United States More Info
Amitkumar Mehta, Site 0005
Contact
205-996-8400
City Of Hope
Duarte California, 91010, United States More Info
Tanya Siddiqi, Site 0016
Contact
626-218-4070
Massachusetts General Hospital-Medical Oncology
Boston Massachusetts, 02114, United States More Info
Jacob Soumerai, Site 0007
Contact
617-792-0547
John Theurer Cancer Center
Hackensack New Jersey, 07601, United States More Info
Lori Leslie, Site 0026
Contact
201-341-5859
University of Cincinnati Medical Center
Cincinnati Ohio, 45219, United States
University of Cincinnati Medical Center-University of Cincinnati Cancer Center
Cincinnati Ohio, 45267, United States
The Ohio State University Wexner Medical Center James Cancer Hospital
Columbus Ohio, 43210, United States More Info
Adam Kittai, Site 0009
Contact
614-366-4567
The University Of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States More Info
David Maloney, Site 0002
Contact
425-246-2946
MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office
Milwaukee Wisconsin, 53226, United States
Local Institution - 0030
Calgary Alberta, T2N 4, Canada
Local Institution - 0042
Halifax Nova Scotia, B3H 2, Canada
Local Institution - 0011
Toronto Ontario, M5G 2, Canada
Local Institution
Marseille , 13008, France More Info
Site 0036
Contact
Local Institution
Rennes , 35033, France More Info
Site 0041
Contact
Local Institution
Villejuif , 94800, France More Info
Site 0028
Contact
Local Institution - 0034
Bergamo , 24127, Italy More Info
Site 0034
Contact
Local Institution - 0032
Bologna , 40138, Italy More Info
Site 0032
Contact
Local Institution
Milano , 20132, Italy More Info
Site 0033
Contact
Local Institution - 0024
Barcelona , 08035, Spain More Info
Site 0024
Contact
Local Institution
Madrid , 28040, Spain More Info
Site 0017
Contact
Local Institution
Salamanca , 37007, Spain More Info
Site 0040
Contact
Local Institution - 0037
Cambridge , CB2 0, United Kingdom
Local Institution - 0021
Leeds , LS9 7, United Kingdom
Local Institution - 0035
London , NW12P, United Kingdom
Local Institution - 0014
Manchester , M20 4, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Chronic Lymphocytic Leukemia

Phase:

Phase 1

Estimated Enrollment:

65

Study ID:

NCT05244070

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.